Danaher (DHR) Stock Forecast & Price Target

$209.86 +1.91 (+0.92%)

Closing price 02/21/2025 03:59 PM Eastern

Extended Trading

$210.91 +1.05 (+0.50%)

As of 02/21/2025 07:58 PM Eastern

Danaher - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 21 Analyst Ratings

Sell
0

Hold
6

Buy
15

Based on 21 Wall Street analysts who have issued ratings for Danaher in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 6 have given a hold rating, and 15 have given a buy rating for DHR.

Consensus Price Target

$278.00
32.47% Upside

According to the 21 analysts' twelve-month price targets for Danaher, the average price target is $278.00. The highest price target for DHR is $315.00, while the lowest price target for DHR is $240.00. The average price target represents a forecasted upside of 32.47% from the current price of $209.86.

Get the Latest News and Ratings for DHR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Danaher and its competitors.

DHR Analyst Ratings Over Time

Type	Current Forecast 2/23/24 to 2/22/25	1 Month Ago 1/24/24 to 1/23/25	3 Months Ago 11/25/23 to 11/24/24	1 Year Ago 2/23/23 to 2/23/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	15 Buy rating(s)	15 Buy rating(s)	14 Buy rating(s)	9 Buy rating(s)
Hold	6 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$278.00	$285.55	$287.16	$266.00
Forecasted Upside	32.47% Upside	16.20% Upside	21.76% Upside	4.79% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

DHR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DHR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Danaher Stock vs. The Competition

Type	Danaher	Medical Companies	S&P 500
Consensus Rating Score	2.71	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	32.47% Upside	29,211.91% Upside	14.36% Upside
News Sentiment Rating	Positive News See Recent DHR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/3/2025	Raymond James 4 of 5 stars	Andrew Cooper Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
1/30/2025	Citigroup 3 of 5 stars	Patrick Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$285.00 ➝ $265.00	+18.75%
1/30/2025	Royal Bank of Canada 4 of 5 stars	Conor McNamara Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$299.00 ➝ $277.00	+24.06%
1/30/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Couillard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$280.00 ➝ $240.00	+7.57%
1/30/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$275.00 ➝ $240.00	+7.57%
1/29/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tycho Peterson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$285.00 ➝ $260.00	+16.53%
1/28/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$310.00 ➝ $300.00	+20.76%
1/28/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Catherine Schulte Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$277.00 ➝ $268.00	+7.86%
12/23/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nam Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$265.00	+15.95%
12/19/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$275.00	+20.46%
Get the Latest News and Ratings for DHR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$290.00 ➝ $290.00	+23.67%
10/31/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Schenkel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$285.00	+17.61%
10/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$310.00 ➝ $315.00	+23.29%
10/23/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Johnson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$315.00 ➝ $315.00	+23.29%
10/23/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$309.00 ➝ $305.00	+19.66%
10/23/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$250.00 ➝ $265.00	+3.97%
10/23/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$290.00 ➝ $310.00	+19.45%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	V. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$275.00 ➝ $278.00	+1.41%
7/24/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$275.00 ➝ $280.00	+5.22%
7/24/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$225.00 ➝ $250.00	-6.32%
4/17/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$250.00 ➝ $280.00	+16.93%
5/1/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$300.00	+26.63%
4/27/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$310.00 ➝ $275.00	+18.29%
4/26/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Larew Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/26/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$300.00 ➝ $270.00	+16.38%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:03 AM ET.

Should I Buy Danaher Stock? DHR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, February 19, 2025. Please send any questions or comments about these Danaher pros and cons to contact@marketbeat.com.

Danaher
Bull Case

Here are some ways that investors could benefit from investing in Danaher Co.:

Danaher Co. reported earnings per share (EPS) of $2.14 for the latest quarter, meeting analysts' expectations, which indicates strong financial performance and stability.
The company has a solid return on equity of 10.82%, suggesting effective management and profitability relative to shareholder equity.
Danaher Co. has a net margin of 16.33%, reflecting its ability to convert revenue into profit efficiently, which is a positive indicator for potential investors.
Recent analyst upgrades, including a price target increase from KeyCorp to $310.00, suggest that market sentiment is favorable and that the stock may have growth potential.
The current stock price is approximately $224.13, which may present a buying opportunity for investors looking for value in a well-performing company.

Danaher
Bear Case

Investors should be bearish about investing in Danaher Co. for these reasons:

Despite positive earnings, some analysts have downgraded their ratings, such as StockNews.com moving from a "buy" to a "hold," indicating potential concerns about future performance.
Wells Fargo & Company recently reduced their price target for Danaher Co. from $280.00 to $240.00, which may signal a lack of confidence in the stock's short-term growth.
Insider selling activity, with a senior vice president selling 5,700 shares, could raise concerns about the company's future prospects and insider confidence.
The dividend yield is relatively low at 0.53%, which may not attract income-focused investors looking for higher returns from dividends.
With a payout ratio of 20.45%, while sustainable, it indicates that a significant portion of earnings is being retained rather than distributed to shareholders, which may limit immediate returns.

DHR Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Danaher is $278.00, with a high forecast of $315.00 and a low forecast of $240.00.
: 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last year. There are currently 6 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DHR shares.
: According to analysts, Danaher's stock has a predicted upside of 32.47% based on their 12-month stock forecasts.
: Over the previous 90 days, Danaher's stock had 1 upgrade by analysts.
: Danaher has been rated by research analysts at Bank of America, Barclays, Citigroup, Guggenheim, Jefferies Financial Group, JPMorgan Chase & Co., Raymond James, Robert W. Baird, Royal Bank of Canada, Scotiabank, and Wells Fargo & Company in the past 90 days.
: Analysts like Danaher less than other "medical" companies. The consensus rating score for Danaher is 2.71 while the average consensus rating score for "medical" companies is 2.82. Learn more on how DHR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:DHR) was last updated on 2/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Danaher (DHR) Stock Forecast & Price Target